EXPERIMENTAL TISSUE SHARED RESOURCE

实验组织共享资源（ETR）的主要目标是为癌症中心的基础、转化和临床研究人员提供获取和分析人类和动物组织的途径。一个关键的优势是，这个核心利用的技术和专业知识的病理和检验医学系。目前提供三项服务：i)组织组织学和免疫组织化学；Ii)组织库；组织分析，包括激光捕获显微镜，形态测量和图像定量和基因分型服务。自上一期资助启动以来，已有63家CFCCC成员使用。在使用方面有所增长，特别是在组织学/免疫组织化学成分中，它占ETR使用的大部分。在之前的资助期内，组织学部分以低于市场的充值率和较短的周转时间为52个不同的CFCCC成员提供了高质量的服务，这些成员主要从事人类癌症标本的转化研究或研究人类癌症的啮齿动物模型。如有需要，我们可根据会员的特殊需求提供定制服务。这些特性使我们的组织学服务优于商业供应商提供的服务，从而促进了使用率的增长。在前一个供资期间，ETR服务为43份出版物作出了贡献，其中36份使用组织学服务。21名CFCCC调查员使用了组织库服务。15名研究人员使用的分析服务对从事转化和临床研究项目的研究人员特别有价值。在这次更新中，我们建议扩大以满足对组织学服务日益增长的需求，保持我们的专业分析服务，通过专注于前列腺癌的综合银行来加强我们的组织采购活动，并提供新的小鼠病理服务，这将有助于CFCCC研究人员对人类癌症的基因工程小鼠模型进行初步表征。

The primary objective of the Experimental Tissue Shared Resource (ETR) is to provide basic, translational, and clinical researchers within the Cancer Center access to, and analysis of, human and animal tissues. A key advantage is that this Core leverages the technical and professional expertise of the Department of Pathology and Laboratory Medicine. Three services are currently offered: i) tissue histology and immunohistochemistry; ii) tissue banking; and iii) tissue analysis, including laser capture microscopy, morphometry and image quantitation and genotyping services. Since the Core was initiated in the prior funding period, 63 CFCCC Members have used it. There has been growth in use, especially in the histology/immunohistochemistry component, which accounts for the majority of usage within the ETR. In the prior funding period, the histology component has provided high-quality service at below-market recharge rates, with short turn-around times to 52 different CFCCC Members who are mainly pursuing translational research on human cancer specimens or studying rodent models of human cancer. When required, we customized services to meet the special needs of CFCCC Members. These features have made our histology services superior to those available from commercial vendors, contributing to usage growth. ETR services contributed to 43 publications in the prior funding period, including 36 using histology services. Tissue banking services were used by 21 CFCCC investigators. Analytical services, used by 15 investigators, have been particularly valuable to investigators pursuing translational and clinical research projects. In this renewal, we propose to expand to meet an increased demand for histology services, maintain our specialty analytical services, strengthen our tissue procurement activities by focusing on comprehensively banking prostate cancers and provide a new mouse pathology service which will assist CFCCC investigators in the initial characterization of genetically engineered mouse models of human cancer.